Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the United States

Overactive bladder (OAB) and benign prostatic hyperplasia (BPH) are highly prevalent conditions that place a large burden on the United States (US) health care system. We sought to analyze patterns of prescription medication usage for incident OAB in men and women, and for incident BPH in men using US health insurance claims data.

This study used Truven Health MarketScan® Commercial and Medicare Supplemental Research databases. The data were pooled from diverse points of care. BPH subjects included men age 18+ with the first and last two diagnoses of BPH ≥30 days apart and no BPH diagnosis for 1 year prior. OAB subjects included men and women age 18+, who were diagnosed similarly with incident OAB. The type of medication, medication continuation (persistence), and switching to a different medication were analyzed through September 30, 2013.

Medication persistence was much higher overall for BPH than OAB (56% vs 34%, respectively, P < 0.0001), and was highest among men with BPH age 65+ (62%). Patients age 18-64 were less likely to continue medication than older adults (age 65+) for both BPH and OAB. A 9.4% of patients in the OAB cohort and 6.9% of men with BPH switched from one medication to another.

Persistence was higher with BPH than OAB medications overall, whereas switching rates were higher in the OAB group. The lower persistence of OAB medication may be due to less efficacy or tolerability. The possibility of under treatment of OAB also warrants future investigations.

Neurourology and urodynamics. 2017 Apr 28 [Epub ahead of print]

Jennifer T Anger, Howard B Goldman, Xuemei Luo, Martin O Carlsson, Douglass Chapman, Kelly H Zou, David Russell, Fady Ntanios, Canan B Esinduy, J Quentin Clemens

Cedars-Sinai Medical Center, Beverly Hills, CA., Lerner College of Medicine, Cleveland Clinic, Cleveland, OH., Pfizer Inc, New York, NY., University of Michigan, Ann Arbor, MI.